Metformin Cessation and Dementia Incidence
Main finding · All-cause incident dementiaResult — go to the resultHazard ratio 1.21 95% CI 1.12–1.30Authors' conclusion
In this study, terminating metformin treatment was associated with increased dementia incidence. This finding may have important implications for clinical treatment of adults with diabetes and provides additional evidence that metformin is associated with reduced dementia risk.
Study context
- Population
- Metformin users with diabetes born prior to 1955 without history of diagnosed kidney disease at metformin initiation, Kaiser Permanente Northern California; follow-up 1996–2020matched cohort
- Participants
- 12,220 vs 29,126
- Exposure
- Early metformin termination vs routine metformin use
- Early terminatorsn = 12,220
- Routine usersn = 29,126reference
- Outcome
- All-cause incident dementia
Methodological detailsmatched on age, gender and diabetes duration, single integrated health care system
- Matched on age, gender and diabetes duration
- Single integrated health care system
Main finding
As reported in the abstract
Hazard ratio
1.21
95% CI 1.12–1.30
Early terminatorsvs Routine users
HR 1.21 (95% CI 1.12–1.30)
Observational data: associations, not effects.
Further findings
Mediation by changes in HbA1c or insulin use · 1 and 5 years after termination
Years
- Mediated contribution, insulin use at 5 years after termination
- 0.00 (95% CI, −0.02 to 0.02 years)
- Mediated contribution, HbA1c at 1 year after termination
- 0.07 (95% CI, 0.02 to 0.13 years)
- Association largely independent of changes in HbA1c and insulin usage
Original publication
Metformin Cessation and Dementia Incidence. JAMA Netw Open. Published 2 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →